Compare AbbVie Inc (ABBV) vs Under Armour Inc Class A (UA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Under Armour Inc Class A — how do they compare? AbbVie Inc trades at $253.61 (market cap $449.91B), while Under Armour Inc Class A trades at $6.35 (market cap $2.84B). The key difference: AbbVie Inc is far larger — about 158.4× Under Armour Inc Class A's market cap, and AbbVie Inc pays a 2.72% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| ABBV | UA | |
|---|---|---|
Market Cap | $449.91B | $2.84B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $7.88 |
52-Week Low | $184.85 | $3.96 |
Enterprise Value | $513.38B | $4.47B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Under Armour (UA) trades at $6.64, up 2.47% with a bullish technical signal from moving averages despite bearish oscillators. The company reported mixed Q1 2026 results, missing EPS expectations after beating in previous quarters. Revenue declined to $5.0B in 2026 with a net loss of -$496M, though valuation remains reasonable with P/S of 0.57. Recent news highlights a Dodge collaboration and insider buying by Prem Watsa.
The outlook remains challenging with declining revenue and negative profitability, but analyst consensus leans positive with 40% buy ratings. Key risks include sustained revenue declines and competitive pressures, while potential catalysts include premium product focus and inventory discipline. The stock presents a turnaround opportunity with significant execution risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
